chimerix_logo.jpg
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
04 déc. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24 nov. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
chimerix_logo.jpg
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
16 nov. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
02 nov. 2023 07h00 HE | Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies;...
chimerix_logo.jpg
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
26 oct. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix to Participate in Upcoming Investor Conferences
05 sept. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
16 août 2023 10h05 HE | Chimerix, Inc.
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts...
chimerix_logo.jpg
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
03 août 2023 07h00 HE | Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in...
chimerix_logo.jpg
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
27 juil. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
27 juin 2023 16h05 HE | Chimerix, Inc.
Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix,...